JMF
CUE icon

Johnson Midwest Financial’s Cue Biopharma CUE Stock Holding History

Johnson Midwest Financial’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10
Closed -$1.07K – 372
2023
Q1 		$1.07K Buy
+10
New +$954 ﹤0.01% 352

Other funds holding CUE

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Johnson Midwest Financial's CUE Position: Q2 2023 in Review

Johnson Midwest Financial sold out of Cue Biopharma (CUE) in Q2 2023, closing a stake of 10 shares — an estimated $1.07K sold.

Johnson Midwest Financial first reported a position in CUE in Q1 2023 and held it in 1 quarter. The position peaked at $1.07K in Q1 2023. 78 funds tracked by Wall St. Rank hold CUE as of Q2 2023.

  • Johnson Midwest Financial reported no remaining Cue Biopharma position as of Q2 2023 after selling out during the quarter.
  • Johnson Midwest Financial sold 10 Cue Biopharma shares in Q2 2023, an estimated $1.07K.
  • Johnson Midwest Financial first reported a position in Cue Biopharma in Q1 2023 and held it in 1 quarter.
  • Johnson Midwest Financial's Cue Biopharma position peaked at $1.07K in Q1 2023.
  • 78 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2023.

Based on Johnson Midwest Financial's 13F filing for Q2 2023, filed 20 Jul 2023.